Hospice where staggering 97% of terminal patients survive is accused of defrauding Medicare for $7.45 million

Federal authorities allege $7.45M in fraudulent Medicare billing by operators of 626 Hospice (doing business as St. Francis Palliative Care); early raids led to arrests of the co-owners and DOJ announced eight arrests with federal prosecutors referencing 15 defendants in the broader probe. CBS analysis found over 700 of roughly 1,800 LA County hospices triggered state-audit red flags and HHS OIG estimated $198.1M of suspected hospice fraud in 2023, prompting intensified federal and state enforcement and a California moratorium on new hospice licenses extended through January 2027.

Analysis

Regulatory and enforcement pressure will act like a near-term choke on the supply side of hospice providers: moratoria, tighter licensure and stepped‑up audits create a 12–24 month window where compliant, well‑capitalized operators and buyers of clean assets can extract pricing power and roll up smaller, distressed players. Expect transaction activity to pick up as private equity owners facing potential clawbacks de‑risk by disposing of hospice and home‑health platforms—sales will be at a discount if audits start to hit cash flows or reserves.

Audit and recovery mechanics imply concentrated cash‑flow risk for small providers: historic enforcement campaigns produce clawbacks and settlements equal to single‑digit to low‑double‑digit percentages of revenue in affected cohorts within 6–18 months, which is large enough to push highly levered platforms into distress and force rapid consolidation. That dynamic disproportionately impacts companies with thin compliance infrastructure and heavy reliance on Medicare FFS hospice lines, while large payers and vendors of claims/audit technology see rising demand for validation services.

Political attention makes this a multi‑year regulatory cycle rather than a one‑off headline; congressional probes and OIG reports act as catalysts spaced over quarters, and enforcement intensity will ebb and flow with legal wins, administrative rulemaking, and election outcomes. A reversal would come from either judicial limits on enforcement or federal policy easing (e.g., clearer eligibility guidance and faster remediation pathways), but those are 9–24 month tail risks rather than immediate offsets.

Key Decisions for Investors

• Long UnitedHealth (UNH) — buy a 12–18 month call spread or outright shares sized 1–2% NAV; rationale: large payers/Optum platforms capture upside from cleaner claims and higher negotiated rates as small providers exit. Target 12–18 month upside 12–20%, stop 8–10% below entry.
• Long Humana (HUM) — add on regulatory weakness (1%–1.5% NAV). Humana’s MA exposure benefits from lower improper payment leakage; use 9–15 month calls to limit capital. Risk: regulatory headwinds to MA pricing; target 10–18% upside vs 10% downside.
• Long R1 RCM (RCM) or similar revenue‑cycle/audit vendors (1% NAV) — enforcement increases demand for audit, compliance and recovery tech over 6–18 months. Entry: buy shares or 9–12 month calls, target 30–50% upside if market re‑rates, stop 15%.
• Pair trade: long UNH/HUM vs short Amedisys (AMED) — size long leg 1.5% NAV, short AMED 0.75% NAV (or buy puts). Short rationale: smaller hospice operators face outsized clawback risk and liquidity stress over next 6–12 months. Profit if audits compress EV/EBITDA multiples by 20–40% on exposed operators.
• Tactical watch: set alerts for OIG/DOJ announcements and House Oversight subpoenas — any major report or indictment should amplify short squeezes in small hospice names and be used to scale pair trades within 24–72 hours.